THE PI3K INHIBITOR PAXALISIB COMBINES SYNERGISTICALLY WITH THE MEK INHIBITOR MIRDAMETINIB TO TARGET ATYPICAL TERATOID/RHABDOID TUMORS-MedSci.cn - 梅斯（MedSci）

THE PI3K INHIBITOR PAXALISIB COMBINES SYNERGISTICALLY WITH THE MEK INHIBITOR MIRDAMETINIB TO TARGET ATYPICAL TERATOID/RHABDOID TUMORS

Malebranche, K; Findlay, T; Geethadevi, A; Eberhart, C; Raabe, E; Rubens, J

NEURO-ONCOLOGY, 2023; 25 ():

科室
- - 订阅+
  - 更多科室
工具
服务